 |
 |
 |
|
 | |||||
| |||||||||
 | |||||||||
|
|
 |
|
|
FDA approves Erbitux (cetuximab) to treat patients with advanced colorectal cancer that has spread to other parts of the body. Erbitux is the first monoclonal antibody approved to treat this type of cancer and is indicated as a combination treatment to be given intravenously with irinotecan, another drug approved to fight colorectal cancer, or alone if patients cannot tolerate irinotecan. Date created: February 12, 2004; updated April 8, 2004 |
|
|
||||||
 | ||||||
|
||||||